Voyager Q3 net loss narrows to $9.0M; new Novartis capsid license; VY7523 SAD data H1 2025

Voyager Therapeutics, Inc.

2024-Q3 EPS reported -$0.53 revenue$73,723,000

Q3 collaboration revenue $24.6M (up from $4.6M YoY); net loss $9.0M vs $25.9M.
Licensed TRACER capsid to Novartis for undisclosed rare neurologic target; $15M upfront, up to $305M milestones.
Neurocrine partnership selected 3rd development candidate, triggering $3M milestone.
VY7523 anti-tau antibody SAD trial enrollment complete; top-line safety/PK data expected H1 2025.
Cash $345.4M at Sep 30; plus $18M received in Oct; runway into 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.